The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders such as Him & Hers (HIMS). Read more here.
Novo Nordisk NVO has outperformed the market over the past 10 years by 3.2% on an annualized basis producing an average annual return of 14.24%. Currently, Novo Nordisk has a market capitalization of $392.
After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk ( NVO -1.54%) has come down considerably. But I think that not only will the Wegovy maker recover, it'll zoom much higher in the coming years.
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of
Goldman Sachs analysts added Novo Nordisk (NVO) to the firm’s European Conviction List as part of its monthly update. Novo Nordisk’s recent
Amgen, MariTide
· 1d
Amgen Starts Final-Stage Studies of Its Monthly Obesity Drug
· 1d · on MSN
Amgen starts two critical late-stage trials for weight loss drug MariTide
Amgen starts late-stage studies of MariTide
Bill Cassidy countered him, arguing that producing more studies is “plowing over ground that has been plowed over.” If confirmed, Bhattacharya would work under HHS Secretary RFK Jr., who has refused to say that vaccines don’t cause autism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results